Phase II FORTE: Efficacy of KRd With or Without ASCT in Newly Diagnosed Multiple Myeloma According to Risk Status

May 31 - June 4, 2019; Chicago, Illinois
Including ASCT after KRd induction therapy leads to higher persistent MRD negativity rate and reduces risk of early relapse in NDMM.
Format: Microsoft PowerPoint (.ppt)
File Size: 203 KB
Released: June 3, 2019


Provided by the USF Health

Contact Clinical Care Options

For customer support please email:

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

This activity is supported by educational grants from
Celgene Corporation

Related Content

From Clinical Care Options (CCO), download a PDF featuring expert answers to clinician questions on CAR T-cell therapy

person default Caron A. Jacobson, MD Jae H. Park, MD Noopur Raje, MD Released: July 19, 2021

Downloadable slideset with highlights from key blood cancers and nonmalignant blood disorders as presented at EHA Virtual Congress 2021, from Clinical Care Options (CCO)

Prof. Charles Craddock, CBE, FRCP (UK) María-Victoria Mateos, MD, PhD Lydia Scarfò, MD Ali T. Taher, MD, PhD Released: July 16, 2021

Interactive online tool with expert and guideline recommendations for assessing and managing CAR T-cell toxicities, from Clinical Care Options (CCO)

Alix Beaupierre, BSN, RN, OCN Daniel J. DeAngelo, MD, PhD Matthew J. Frigault, MD Shilpa Paul Headshot Shilpa Paul, PharmD, BCOP Noopur Raje, MD Released: July 9, 2021

From Clinical Care Options (CCO), video on CAR T-cell therapy for hematologic malignancies, with Drs. Caron Jacobson, Jae Park, and Noopur Raje

person default Caron A. Jacobson, MD Jae H. Park, MD Noopur Raje, MD Physicians: maximum of 1.75 AMA PRA Category 1 Credits Released: July 9, 2021 Expired: July 8, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.